Physician profile
Jerome Aul
NPI 1053349985
$4,099.18
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,973 · 2020: $700 · 2021: $952 · 2022: $429 · 2023: $45.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $662.54 | 2019-2023 | Xtampza |
| Biodelivery Sciences International, INC. | $638.23 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $466.96 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $377.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.09 | 2019-2023 | Relistor |
| Pfizer INC. | $324.65 | 2019-2021 | |
| Horizon Therapeutics Plc | $125.82 | 2020-2022 | |
| Medtronic, INC. | $120.76 | 2021 | |
| Tersera Therapeutics LLC | $112.65 | 2019 | |
| Virtus Pharmaceuticals LLC | $106.70 | 2021 | |
| Redhill Biopharma INC. | $92.91 | 2020-2021 | |
| Grt US Holding, INC. | $89.22 | 2022 | |
| Almatica Pharma LLC | $59.38 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $50.49 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $38.14 | 2019 | |
| Hikma Pharmaceuticals USA | $37.26 | 2022 | |
| Ibsa Pharma INC. | $37.01 | 2020-2021 | |
| Lilly USA, LLC | $36.15 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $32.53 | 2021 | |
| Abbvie INC. | $32.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.18 | 2019 | |
| Mdd US Operations, LLC | $28.51 | 2019 | |
| Shionogi INC | $23.61 | 2019 | |
| Baudax Bio INC. | $21.33 | 2022 | |
| Si-Bone, INC. | $16.97 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $16.73 | 2022 | |
| Pacira Therapeutics, INC. | $16.47 | 2019 | |
| Assertio Therapeutics, INC. | $15.95 | 2019 | |
| Kaleo, INC. | $15.82 | 2019 | |
| Averitas Pharma INC. | $15.76 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Aul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.